Embla Medical hf.
OSSFF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.78 | 0.25 | -1.00 | -1.68 |
| FCF Yield | 2.44% | 0.72% | 0.43% | 2.03% |
| EV / EBITDA | 39.46 | 48.00 | 63.95 | 47.29 |
| Quality | ||||
| ROIC | 1.86% | 1.74% | 1.19% | 1.71% |
| Gross Margin | 58.21% | 58.10% | 58.67% | 59.18% |
| Cash Conversion Ratio | 1.80 | 0.66 | 0.62 | 1.32 |
| Growth | ||||
| Revenue 3-Year CAGR | 5.49% | 5.35% | 5.54% | 5.96% |
| Free Cash Flow Growth | 246.38% | 56.76% | -77.50% | 3.69% |
| Safety | ||||
| Net Debt / EBITDA | 8.40 | 10.55 | 12.65 | 9.36 |
| Interest Coverage | 5.98 | 6.57 | 4.16 | 5.58 |
| Efficiency | ||||
| Inventory Turnover | 0.59 | 0.63 | 0.54 | 0.64 |
| Cash Conversion Cycle | 178.43 | 165.28 | 183.78 | 165.97 |